Table 1. Validation of the mADAMTS13 detection ELISA’s.
| Repeatability (CV, %) | Reproducibility (CV, %) | |||||
|---|---|---|---|---|---|---|
| Dilution of NMP | 9F2 | 14H7 | 20A10 | 9F2 | 14H7 | 20A10 |
| 1/5 | 2 | 3 | 3 | 4 | 5 | 7 |
| 1/10 | 3 | 3 | 3 | 4 | 5 | 6 |
| 1/20 | 4 | 4 | 4 | 5 | 6 | 6 |
| 1/40 | 4 | 4 | 3 | 9 | 7 | 5 |
| 1/80 | 5 | 4 | 7 | 6 | 5 | 17 |
| 1/160 | 4 | 3 | 5 | 5 | 4 | 8 |
| 1/320 | 5 | 5 | 5 | 11 | 14 | 6 |
| 1/640 | 5 | 4 | 5 | 5 | 7 | 6 |
| 1/1280 | 6 | 9 | 6 | 13 | 16 | 7 |
| 1/2560 | 9 | 6 | 6 | 23 | 8 | 8 |
Anti-mADAMTS13 mAbs 9F2, 14H7 and 20A10 were coated, different dilutions of NMP were added and bound plasma mADAMTS13 was detected with the polyclonal anti-mADAMTS13 rabbit IgG and GAR-HRP. The CV (%) was calculated for each dilution.